Metastatic breast cancer (MBC) prognosis is variable, depending on several clinical and biological factors. A better prediction of a patient’s outcome could allow for a more accurate choice of treatments. The role of serum biomarkers in predicting outcome remains unclear in this setting. | The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases